The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T

Abstract

Sipuleucel-T is an immunotherapy indicated for the treatment of metastatic prostate cancer. It offers a new mechanism to treat prostate cancer without the side effects of hormone therapies and chemotherapies. In previous studies sipuleucel-T did not delay disease progression, but demonstrated an overall survival benefit compared to placebo. While clinical… (More)
DOI: 10.3390/cancers5020511

Topics

4 Figures and Tables

Cite this paper

@inproceedings{Ng2013TheLO, title={The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T}, author={Laura Ng and Wendy D Heck and Stacey M Lavsa and David Crowther and Brad Atkinson and Lianchun Xiao and John Araujo}, booktitle={Cancers}, year={2013} }